

BIBLIOGRAFIA



- Abdelmalek MF, Angulo P, Jorgensen RA, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine a promising new agent for patients with non-alcoholic steatohepatitis: results of a pilot study. *Am J Gastroenterol*. 2001; 96:2711-2717.
- Abdelwahab E. Ultrastructure and arrangement of hepatocyte cords in the duckling's liver. *J Anat*. 1987;150:181-189.
- Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. *Diabet Med* 2005; 22:1129-1133.
- Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. *J Hepatol* 2005;42:132-138.
- Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifyline in non-alcoholic steatohepatitis. *Am J Gastroenterol* 2004;99:2365-8.
- AGA Technical review on non-alcoholic fatty liver disease. *Gastroenterology* 2002;123:1705-1725.
- Alwayn PJ, Andersson C, Lee S, Arsenault DA, Bristian B. Inhibition of matrix metalloproteinases increases PPAR- α and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. *AJP-Gastrointest Liver Physiol* 2006;291(6):G1011-G1019.
- Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. *J Hepatol*. 1991; 12: 224-229.
- Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. *Hepatology* 1999;30:1356-62.
- Angulo P, Lindor KD. Treatment of non-alcoholic fatty liver: present and emerging therapies. *Semin Liver Dis* 2001;21:81-88.

- Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med.* 2002;346(16):1221-31.
- Anonymous. Integrated management of cardiovascular risk. Geneva: World Health Organization, 2002:1-36.
- Anonymous. Top 200 brand-name drugs by units in 2002. *Drug Top* 2003;6:60-2.
- Aoki T, Yoshinaka Y, Yamazaki H, Suzuki H, Tamaki T, Sato F, Kitahara M, Saito Y. Triglyceride-lowering effect of pitavastatin in a rat model of postprandial lipemia. *Eur J Pharmacol* 2002;444:107-113.
- Arthur MJP. Matrix degradation in the liver. *Semin Liver Dis* 1990;10:47-55.
- Ayala I, Garcia Pérez B, Doménech G, Castells MT, Valdés M. Use of the chicken as an experimental animal model in atherosclerosis. *Avian and Poultry Biology Reviews.* 2005;16:151-159.
- Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. *Gastroenterology* 1994;107:1103-9.
- Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. *Diabetes.* 2003;52:1364-1370.
- Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. *J Am Med Assoc* 1996;275:128-133.
- Baldridge AD, Perez-Atayde AR, Graeme-Cook F. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. *J Pediatr* 1995;127:700-704.

- Baptista A, Bianchi L, de Groote J. Alcoholic liver disease: morphological manifestations. Review by an international group. *Lancet* 1981;1:707-11.
- Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with non-alcoholic steatohepatitis. *J Hepatol.* 1999; 31:384.
- Bataller R, Schwabe RF, Choi YH, Yang K, Palk YH, Lindquist J. NADPH oxidative signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. *J Clin Invest* 2003;112:1383-94.
- Batman AP, Scheuer PJ. Diabetic hepatitis preceding the onset of glucose intolerance. *Histopathology* 1985;9:237-243.
- Becker U, Deis A, Sørensen TI, Grønbaek M, Borch-Johnsen K, Müller CF, Schnohr P, Jensen G. Prediction of risk of liver disease by alcohol intake, sex and age: a prospective population study. *Hepatology* 1996;23:1025-1029.
- Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F. Prevalence of and risk factors for hepatic steatosis in northern Italy. *Ann Intern Med* 2000;132:112-117.
- Bennett BL, Satoh Y, Lewis AJ. JNK: A new therapeutic target for diabetes. *Curr Opin Pharmacol* 2003;3:420-5.
- Bergamini CM, Gambetti S, Dondi A, and Cervellati C. Oxygen species and tissue damage. *Curr Pharm Des.* 2004;21:983-989.
- Bianchi L and Gudat F. Chronic hepatitis. In MacSween RNM, Anthony PP, Scheuer PJ, Portmann B, and Burt AD, eds. *Pathology of the liver*, 3rd edn. Edinburgh: Churchill Livingstone, 1994:394-95.
- Bird GL, Williams R. Factors determining cirrhosis in alcoholic liver disease. *Mol Aspects Med* 1988;10:97-105.
- Bisgier C, Essenburg A, Auerbach B, Pape M, Sekerke C, Gee A, Wölle S, Newton R. Attenuation of plasma low density lipoprotein

- cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. *J Lipid Res* 1997;38(12):2502-15)
- Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. *Hepatology* 2005;42:481-489.
 - Blendis L, Oren R, Halpen Z. NASH: can we iron out the pathogenesis?. Selected summary. *Gastroenterology* 2000;118:981-3.
 - Boker KHW, Phele B, Steinmetz C, Breitenstein K, Bahr M, Lichtinghagen R. Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis. *Hepato-gastroenterol* 2000;47:812-9.
 - Bolego C, Baetta R, Bellostta S, Corsini A, Paoletti R. Safety considerations of statins. *Curr Opin Lipidol* 2002;13:637-644.
 - Bonkovsky HL, Jawaid Q, Tortorelli K et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. *J Hepatol* 1999;31:421-429.
 - Brown, A.G., T.C. Smale, T.J. King, R. Hasenkamp, and R.H. Thompson. Crystal and molecular structure of compactin, a new antifungal metabolite from *Penicillium brevicompactum*. *J. Chem. Soc. Perkin I.* 1976; 1165-1170
 - Browning J, Horton J. Molecular mediators of hepatic steatosis and liver injury. *J Clin Invest* 2004;114:147-152.
 - Browning J, Szczepaniak L, Dobbins R, Nuremberg P, Horton J, Cohen J. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004;40:1387-95.
 - Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *Am J Gastroenterol* 1999;94:2467-74.

- Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. *Semin Liver Dis* 2001; 21: 3-16.
- Brunt EM, Tiniakos DG. Pathology of steatohepatitis (review). *Best Pract Res Clin Gastroenterol* 2002;16:691-707.
- Brunt EM. Alcoholic and nonalcoholic steatohepatitis. *Clin Liver Dis* 2002;6:399-420.
- Brunt EM. Nonalcoholic steatohepatitis. *Semin Liver Dis* 2004;24 (1):3-20.
- Bugianesi E, McCullough AJ, Marchesini J. Insulin resistance: a metabolic pathway to chronic liver disease. *Hepatology*. 2005;42:987-1000.
- Bult H, Heman AG, Matthys KE. Antiatherosclerotic activity of drugs in relation to nitric oxidase function. *Eur J Pharmacol* 1999;375:157-76.
- Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. *Semin Diagn Pathol* 1998;15:246-258.
- Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. *Hepatology* 1999;29:664-669.
- Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK. Mitochondrial abnormalities in non-alcoholic steatohepatitis. *J Hepatol* 1999;31:430-4.
- Canbay A, Taimr P, Torok N, Higuch H, Friedman S, Gores GJ. Apoptotic body engulfment by human stellate cell line is profibrogenic. *Lab Invest* 2003;83:655-63.
- Carmena R. Papel de los inhibidores de la HMG-CoA reductasa en el tratamiento actual de las hiperlipidemias. *Rev Esp Cardiol* 1995;48:59-65.

- Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. *Gastroenterology* 2004;126:1287-92.
- Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. *Hepatology* 2005;41:690-695.
- Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, Rosen CB, Batts KP. Frequency of non-alcoholic steatohepatitis as a cause of advanced liver disease. *Liver Transpl* 2001;7:608-14.
- Chen J, Petersen DR, Schenker S, Henderson GI. Formation of malondialdehyde adducts in livers of rats exposed to ethanol: Role in ethanol-mediated inhibition of cytochrome c oxidase. *Alcohol Clin Exp Res* 2000;24:544-52.
- Cherian G, George MP. Hepatic lipid characteristic and histopathology of laying hens fed CLA or n-3 fatty acids. *Lipids* 2004;39: 31-6.
- Cherian G, Holsonbake T, Goeger M, Bildfell R. Dietary CLA alters yolk and tissue FA composition and hepatic histopathology of laying hens. *Lipids* 2002;37(8): 751-757.
- Chitturi S, Farrell G. Etiopathogenesis of nonalcoholic steatohepatitis. *Semin Liver Dis* 2001; 21(1):27-41.
- Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. *Semin Liver Dis* 2002;22:169-183.
- Chojkier M, Houglum K, Solis-Herruzo J, Brenner DA. Stimulation of collagen gene expression by ascorbic acid in cultured human fibroblasts. A role for lipid peroxidation? *J Biol Chem* 1989;264:16957-62.

- Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. *Gastroenterology* 2002;122:1649-1657.
- Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. *Am J Gastroenterol* 2003;98:960-7.
- Clark JM, Diehl AM. Defining non-alcoholic fatty liver disease: implications for epidemiologic studies. *Gastroenterology* 2003;124:248-250.
- Coates RA, Halliday ML, Rankin JG, Feinman SV, Fisher MM. Risk of fatty liver infiltration of cirrhosis of the liver in relation to ethanol consumption: a case-control study. *Clin Invest Med* 1986;9:26-32.
- Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. *Am J Cardiol* 2006;97[suppl]:77C-81C.
- Comar KM, Sterling RK. Drug therapy for non-alcoholic fatty liver disease. *Aliment Pharmacol Ther.* 2006; 23: 207-215.
- Conde K, Vergara-Jiménez M, Krause BR, Newton RS, Fernández ML. Hypercholesterolemia actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in guinea pigs. *J Lipid Res* 1996; 37: 2372-2382.
- Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. *Liver Transpl* 2001;7:363-373.
- Cortez-Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC. Tamoxifen-associated steatohepatitis report of three cases. *J Hepatol* 1995;23:95-97.
- Cortez-Pinto H, Batista A, Camilo ME, de Moura MV. Hepatic stellate cell activation occurs in non-alcoholic steatohepatitis. *Hepatogastroenterology* 2001;48:87-90.

- Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome?. *Clin Nutr* 1999;18:353-835.
- Cotrim HP, Andrade ZA, Parana R, Portugal M, Lyra LG, Freitas LA. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. *Liver* 1999;19:299-304.
- Cox KL, Burke V, Morton AR, Beilin LJ, Puddey IB. Independent and additive effects of energy restriction and exercise on glucose and insulin concentrations in sedentary overweight men. *Am J Clin Nutr* 2004;80:308-16.
- Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. *Lancet*. 2003 Jan 25;361(9354):296-300.
- Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. *Gut* 2004; 53:750-755.
- Davail S, Rideau N, Guy G, André JM, Hermier D, Hoo-Paris R. Hormonal and metabolic responses to overfeeding in three genotypes of ducks. *Comp Biochem Physiol* 2003;134:707-715.
- Davidson VL, Sitman DB: *Biochemistry*, 3 rd ed. Philadelphia, Harwal, 1994.
- Davignon J, Montingy M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead. *Can J Cardiol* 1992;8:843-864.
- Davila JA, Morgan RO, Shaib Y, McGlynn KA, El Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. *Gut* 2005; 54:533-539.
- Day C, James O. Steatohepatitis: A tale of two "hits"? *Gastroenterology*. 1998;114:842-5 (editorial).

- Day CP. Pathogenesis of steatohepatitis. *Best Pract Res Clin Gastroenterol.* 2002; 16:663-678.
- de Denus S, Spinler SA, Millar K, Peterson AM. Statins and liver toxicity: a meta-analysis. *Pharmacotherapy* 2004;24:584-591.
- Debaere C, Rigauts H, Laukens P. Transient focal fatty liver infiltration mimicking liver metastasis. *J Belge Radiol.* 1998;81(4):174-5.
- Del Gaudio A, Boschi L, Del Gaudio GA, Mastrangelo L, Munari D. Liver damage in obese patients. *Obes Surg* 2002;12:802-4.
- Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Nguyen R, Tinel M. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. *Gastroenterology* 2002;123:1278-90.
- Denk H, Stumptner C, Zatloukal K. Mallory bodies revisited. *J Hepatol* 2000; 32:689-702.
- Desmet VJ, Gerber M, Hoofnagle JH, Manns M, and Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology*, 1994; 19: 1513-20.
- Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in non-alcoholic: a clinical and histologic comparison with alcohol-induced liver disease. *Gastroenterology* 1989;20:594-8.
- Diraison F, Dusserre E, Vidal H, Sothier M, Beylot M. Increased hepatic lipogenesis but decreased expression of lipogenic gene in adipose tissue in human obesity. *Am J Physiol Endocrinol Metab.* 2002;282:E46-E51.
- Dixon JB, Bhatal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. *Hepatology* 2004; 39:1647-1654.

- Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. *Gastroenterology* 2001;121:91-100.
- Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurum J, Boidt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non alcoholic fatty liver disease. *J Clin Invest* 2005; 115:1343-1351.
- Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. *N Engl J Med.* 1970;282(15):829-34.
- Du y Ahn. Dietary CLA affects lipid metabolims in broiler chicks. *Lipids* 2003; 38(5):505-11
- Duzendorfer S, Rothbucher D, Schratzberger P, Reinisch N, Kahler CM, Wiedermann CJ. Mevelonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. *Circ Res* 1997;81:963-9.
- Egawa T, Toda K, Nemoto Y, Ono M, Akisaw N, Saibara T, Hayashi Y, Hiori M, Enzan H, Onishi S. Pitavastain ameliorates severe hepatic steatosis in aromatasedeficient (Ar^{-/-}) mice. *Lipids* 2003;38:519-23.
- Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study. *J Hepatol* 2007;47(1):135-41.
- El-Haschimi K, Pierroz DD, Hileman SM, Bjørbaek C, Flier JS. Two defects contribuye to hypothalamic leptin resistance in mice with diet-induced obesity. *J Clin Invest* 2000;105:1827-1832.
- Elkin R.G., Wood K.V. and Hagey L.R. Biliary bile acid profiles of domestic fowl as determined by high performance liquid chromatography and fast atom bombardment mass spectrometry.

- Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology. 1990;96(1):157-161.
- Elkin RG, Zhong Y, Donkin SS, Hengstschläger-Ottner E, Schneider WJ. Effects of atorvastatin on lipid metabolism in normolipidemic and hereditary hyperlipidemic, non-laying hens. *Comp Biochem Physiol B Biochem Mol Biol.* 2006;143(3):319-29.
 - Endo A, M Kuroda. Citrinin an inhibitor of cholesterol synthesis. *J Antibiot (Japan).* 1976; 29 : 841-843
 - Endo A, Monacolin K. A new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase. *J Antibiot. (Japan).* 1979; 33: 334-336
 - Endo, A, M. Kuroda, Y. Tsujita. ML-236 A, ML-236-B, and ML-236 C, new inhibitors of cholesterol synthesis produced by *Penicillium citrinum*. *J. Antibiot (Japan)*1976; 29: 1346-1348
 - England JD, Viles A, Labib S. Liver side effects associated with simvastatin therapy. *Aust Med J* 1991;155:61.
 - Esterbauer H, Schaur RJ, and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med.*1991;11:81-128.
 - Falchuk KR, Fiske SC, Haggitt RC, Federman M, Trey C. Pericentral hepatic fibrosis and intracellular hyaline in diabetes mellitus. *Gastroenterology* 1980;78:535-41.
 - Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of non-alcoholic steatosis syndromes. *Semin Liver Dis* 2001;21:17-26.
 - Fan CY, Pan J, Chu R, Lee D, Kluckman KD, Usuda N, Singh I, Yeldandi AV, Rao MS, Maeda N, Reddy JK. Targeted disruption of the peroxisomal fatty acyl-CoA oxidase gene: generation of a mouse

- model of pseudoneonatal adrenoleukodystrophy. *Ann N Y Acad Sci* 1996;530-540.
- Farrell GC. Drug-induced steatohepatitis. In *Drug-induced liver disease*. Edinburg: Churchill Livingstone 1994;431-438.
 - Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsias. *Hepatology* 2004; 40:820-826.
 - Federico A, Trappoliere F, Coppola M, D'Auria M. Relationship between dietary intake and liver histology in non-alcoholic fatty liver disease. *J Hepatol* 2006;44 (Supl S2):S251.
 - Feldmann G, Haouzi D, Moreau A, Durand-Schneider AM, Bringier A, Berson A. Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice. *Hepatology* 2000;31:674-83.
 - Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart KJ, Lindor KD. Hepatocyte apoptosis and Fas expression are prominent features of human non alcoholic steatohepatitis. *Gastroenterology* 2003;125:437-43.
 - Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. *J Hepatol* 2003; 39:978-983.
 - Fernández-Real JM, Ricart Engel W, Arroyo E, Balanca R, Casamitjana R, Cabrero D. Serum ferritin as a component of the insulin resistance syndrome. *Diabetes Care*. 1998;21:62-68.
 - Fiatarone JR, Coverdale SA, Batey RG, Farrell GC. Non-alcoholic steatohepatitis impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis. *J Gastroenterol Hepatol* 1991;6:585-90.

- Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among U.S adults. Findings from the Third National Health and Nutrition Examination Survey. *J Am Med Assoc* 2002;455:161-167.
- Franzen LE, Ekstedt M, Kechagias S, Bodin L. Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. *Mod Pathol* 2005;18:912-916.
- French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsies in patients with chronic hepatitis C. *Hepatology* 1994;20:15-20.D
- Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as mechanism of hepatotoxicity. *Pharmacol Ther* 1995;67:101-54.
- Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signalling pathway. *J Biol Chem.* 2002;277:25226-25232.
- Gail M.H., Costantino J.P., Bryant J., Croyle R., Freedman L., Helzlsouer K., Vogel V. Weighim the risks and benefits of tamoxifen treatment for preventing breast cancer. *J Natl Cancer Inst* 1999;91:1829-1846.
- Garcia Perez B, Ayala I, Castells MT, Madrid JF, Ortega MR, Ortega JV, Ballesta J, Fernandez Pardo J, Valdes M. Planimetric and histological study of the aortae in atherosclerotic chickens treated with nifedipine, verapamil and diltiazem. *Histol Histopathol* 2003;18:1027-1033.
- García-Ruiz C, Colell A, Morales A, Kaplowitz N, Fernandez-Checa JC. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear

- factor-kappa B: studies with isolated mitochondria and rat hepatocytes. *Mol Pharmacol.* 1995;48:825-834.
- García-Ruiz I, Rodríguez-Juan C, Díaz-Sanjuan T, Del Hoyo P, Colina F, Muñoz-Yagüe T. Uric acid and anti-TNF α antibody improve mitochondrial respiratory chain dysfunction in ob/ob mice. *Hepatology* 2006;44:581-91.
 - George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. *Gastroenterology* 1998; 114: 311-318.
 - Georgescu E, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. *J Gastrointest Liver Dis.* 2007; 16(1):39-46.
 - Goldstein NS, Hastah F, Galan MV, Gordon SC. Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. *Am J Clin Pathol* 2005; 123:382-387.
 - Gómez E, Mendoza J, Rubio S, Moreno JA, García L, Moreno R. Eficacia de la atorvastatina en el tratamiento del hígado graso no alcohólico [abstract]. *Gastroenterol Hepatol.* 2006;29(Supl 1):172-3.
 - Gotto AM. Safety and statin therapy. Reconsidering the risks and benefits. *Arch Intern Med* 2003;163:657-659.
 - Grabiely I, Ma XH, Yang XM, Rossetti L, Barzilai N. Leptin resistance during aging is independent of fat mass. *Diabetes* 2002;51:1016-1021.
 - Grimbert S, Fisch C, Deschamps D, Berson A, Fromenty B, Feldmann G, Pessayre D. Effects of female sex hormones on mitochondria: possible role in acute fatty liver of pregnancy. *Am J Physiol* 1995;31:G107-G115.

- Grimbert S, Pessayre D, Degott C, Benhamou JP. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. *Dig Dis Sci* 1994;39:2032-2033.
- Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. *Am J Gastroenterol* 1992;87:775-779.
- Ground KE. Liver pathology in aircrew. *Aviat Space Environ Med* 1982;53:14-18.
- Grundy SM. HMG-CoA reductase inhibitors: clinical applications and therapeutic potential. En : Rifkind B, editor *Drug Treatment of Hyperlipidemia*. Nueva York: Marcel Dekker Inc., 1991; 139-167
- Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. *J Gastroenterol Hepatol* 2004;19:854:8.
- Hall P de la. Alcoholic liver disease. In: MacSween RNM, Anthony PP, Scheuer PJ. (eds). *Pathology of the liver*. London: Churchill Livingstone, 1994: 317-349.
- Halsted CH. Obesity: effects on the liver and gastrointestinal system. *Curr Opin Gastroenterol* 1999;15:154-158.
- Hardie DG. Minireview: The AMP-activated protein kinase cascade: the key sensor of cellular energy status. *Endocrinology*. 2003;144:5179-5183.
- Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study fo orlistat treatment in Obese, non-alcoholic steatohepatitis patients. *Aliment Pharmacol Ther*.2004; 20(6):623-628.
- Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis. *Am J Gastroenterol* 2003;98:2485-90.

- Harrison SA, Torgerson S, Hayashi PH. The natural history of non-alcoholic fatty liver disease: a clinical histopathological study. *Am J Gastroenterol* 2003;98:2042-2047.
- Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta 1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. *Aliment Pharmacol Ther* 2001;15:1667-1672.
- Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, Karagiannopoulou G, Tzioufa V, Dimitrios K. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. *Indian J Gastroenterol* 2004;23:131-134.
- Hellerstein MK, Schwarz JM and Neese RA. Regulation of hepatic the novo lipogenesis in humans. *Annu Rev Nutr.* 1996;16:523-557.
- Hensley K, Kotake Y, Sang H, Pye QN, Wallis GL, Kolker LM, Tabatabaie T, Stewart CA, Konishi Y, Nakae D, Floyd RA. Dietary choline restriction causes complex I dysfunction and increased H₂O₂ generation in liver mitochondria. *Carcinogenesis.* 2000;21:983-989.
- Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. *J Hepatol* 2003;39:1042-8.
- Hilden M, Christoffersen P, Juhl E, et al. Liver histology in a "normal" population-examinations of 503 consecutive fatal traffic casualties. *Scand J Gastroenterol* 1977;12:593-597.
- Ho KJ, Lawrence WD, Lewis KA, Liu LB, Taylor CB. Hereditary hyperlipidemia in nonlaying chickens. *Arch Pathol* 1974;98:161-172.
- Hocking MP, Davis GL, Franzini DA. Long-term consequences after jejunoileal bypass for morbid obesity. *Dig Dis Sci* 1998;43:2493-2499.
- Hodges RD. *The histology of the fowl.* Academic Press (London) 1974.

- Horlander JC, Kwo PY, Cummings OW, Kouloulis G. Atorvastatin for the treatment of NASH [abstract]. *Gastroenterology* 2001;120:A544.
- Hübscher SG. Histological assessment of non-alcoholic fatty liver disease. *Histopathology* 2006; 49:450-465.
- Hunninghake DB, Miller VT, Goldberg I, Schonfeld G, Stein EA, Tobert JA. The lovastatin study group II. Lovastatin follow-up ophthalmological data. *JAMA* 1988; 259:354-356.
- Ide T, Tsutsui H, Hayashidani S, Kang D, Suematsu N, Nakamura K, Utsumi H, Hamasaki N, Takeshita A. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. *Circ Res* 2001;88:529-35.
- Ikejima K, Honda H, Yoshikawa H, Hirose M, Kitamura T, Takei Y. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. *Hepatology*. 2001;34:288-97.
- Illingworth DR. HMG-CoA reductase inhibitors. *Curr Opin Lipidol* 1991; 2:24-30
- Ingelman-Sundberg M, Ekstrom G, Tindberg N. Lipid peroxidation dependent on ethanol-inducible cytochrome P-450 from rat liver. *Adv Biophys*. 1988;71:43-47.
- Inoue M, Tazuma S, Hyogo S. Pravastatin, a HMG-CoA reductase inhibitor, attenuates hepatic oxidative stress to retard liver fibrogenesis of NAFLD in an in vivo study: An evidence for therapeutic potential of statins on NASH. *Gastroenterology*. 2006;130:A-828.
- Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. *J Hepatol* 1995;22:696-9.

- Itoh S, Yougel T, Kawagoe K. Comparison between non-alcoholic steatohepatitis and alcoholic hepatitis. *Am J Gastroenterol* 1987; 82:650-654.
- James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. *Lancet* 1999;353:1634-6.
- James OFW, Day CP. Nonalcoholic steatohepatitis (NASH): a disease of emerging identity and importance. *J Hepatol* 1998;29:495-501.
- Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? *Eur J Gastroenterol Hepatol* 2003;15:539-543.
- Kaplan LM. Leptin, obesity, and liver disease. *Gastroenterology*. 1998M115;997-1001.
- Kelley DE, McKolanis TM, Hegazi RAF, Kuller LH, Calan SC. Fatty liver in type 2 diabetes mellitus: Relation to regional adiposity, fatty acids, and insulin resistance. *Am J Physiol Endocrinol Metabol* 2003; 285: E906-E916.
- Kerkar N. Non-alcoholic steatohepatitis in children. *Pediatr Transplantation* 2004; 8:613-618.
- Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferators-activated receptor alpha mediates the adaptive response to fasting. *J Clin Invest* 1999;103:1489-1498.
- Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, et al. Metabolic significance of non-alcoholic fatty liver disease in nonobese, nondiabetic adults. *Arch Intern Med* 2004;164:2169-75.
- Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. *Hepatology* 2002;36:227-242.
- Kinnman N, Hulterantz R. Lipid lowering medication and hepatotoxicity. *J Intern Med* 2001;250:183-185.

- Kiyici M, Gulten M, Gurel S, Nalk SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of non-alcoholic steatohepatitis. *Can J Gastroenterol* 2003;17:713-8.
- Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histologic scoring system for non-alcoholic fatty liver disease. *Hepatology* 2005;41:1313-21.
- Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology* 1981;1:431-5.
- Kogiso T, Moriyoshi Y, Nagahara H. Clinical Significance of high sensitivity c-reactive protein (hs-CRP) in non-alcoholic fatty liver disease (NAFLD). *J Hepatol* 2006;44 (SuppS2):S256,
- Kok N, Roberfroid M, Delzenne N. Dietary oligofructose modifies the impact of fructose on hepatic triacylglycerol metabolism. *Metabolism* 1996;45:1547-1550.
- Koo SH, Dutcher AK, and Towle HC. Glucose and insulin function through two distinct transcription factors to stimulate expression of lipogenic enzyme gene expression. *J Biol Chem*. 2001;276:9437-9445.
- Kopelman PG. Obesity as a medical problem. *Nature* 2000; 404:635-43
- Koteish A, Diehl A. Animal model of steatosis. *Seminars in liver disease* 2001; 21(1):89-104.
- Krahenbuhl S. Alterations in mitochondrial function and morphology in chronic liver disease: pathogenesis and potential for therapeutic intervention. *Pharmacol Ther* 1993;60:1-38.

- Kral J, Schaffner F, Pierson R, Wang J. Body fat topography as an independent predictor of fatty liver. *Metabolism* 1993;42:548-551.
- Kushiya F, Wada H, Ooi K, Sakurai Y, Sakaguchi A, Noda M, Abe Y, Nakasaki T, Tsukada T, Shiku H, Nobori T. Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis. *Am J Hematol* 2005; 78: 1-6.
- Kuyvenhoven JP, Ringers J, Verspaget HW, Lamers CP, van Hoek B: Serum matrix metalloproteinase MMP-2 and MMP-9 in the late phase of ischemia and reperfusion injury in human orthotopic liver transplantation. *Transplant Proc* 2003, 35:2967-2969.
- La Rosa JC, He J, Vupputuri S, Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. *JAMA* 1999; 282:2340-6.
- Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid and clofibrate in the treatment of non-alcoholic-induced steatohepatitis: a pilot study. *Hepatology*.1996;23:1464-1467.
- Law MR, Rudnicka AR. Statin safety: evidence from the published literature. *Am J Cardiol* 2006;97(suppl 8A):52C-60C.
- Lazarow PB: Peroxisomes. En Arias IM (ed): *The liver: Biology and Pathobiology*, 3 rd ed. New York, Raven Press. 1994, p 292.
- Lebensztejn, Sobaniec-Lotowska, Kaczmarek, Sulik. Steatohepatitis with regard to morphological- mainly ultrastructural-picture of oligobipunctate of the liver. *Case Rep Clin Pract Rev*. 2001; 2(3):203-7.
- Leclercq I, Farrell G, Field J, Bell D, Gonzalez F, Robertson G. Cyp2E1 and Cyp4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. *J Clin Invest*. 2000;105:1067-1075.

- Lee RG. Non-alcoholic steatohepatitis: a study of 49 patients. *Hum Pathol* 1989;20:594-598.
- Lee RG. Fatty change and steatohepatitis. In: Lee RG, editor. *Diagnostic liver pathology*. St. Louis: Mosby; 1994. p. 167-94.
- Lee KS, Buch M, Houghlum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-mycb expression. *J Clin Invest* 1995;96:2461-8.
- Lee RG. Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler. *Hepatology* 1995;21:1742-1743.
- Lenanerts J, Verresen L, Van Steenberghe W, et al. Fatty liver hepatitis and type 5 hyperlipoproteinemia in juvenile diabetes mellitus. Case report and review of the literature. *J Clin Gastroenterol* 1990;12:93-97.
- Lettéron P, Brahim-Bourouina N, Robin MA, Moreau A, Feldmann G, Pessayre D. Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta oxidation. *Am J Physiol* 1997;35:G1141-G1150
- Libbrecht L, Desmet V, Van Damme B, Roskams T. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. *J Hepatol* 2000; 33:76-84.
- Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P. Ursodeoxycholic acid for treatment of non-alcoholic steatohepatitis: results of a randomized trial. *Hepatology* 2004;39:770-8.
- Lipitor (atorvastatin) [package insert]. New York, NY: Pfizer Inc.; 2004.
- Ljumovic D, Diamantis I, Alegakis AK, Kouroumalis EA. Differential expression of matrix metalloproteinases in viral and non-viral chronic liver diseases. *Clin Chim Acta* 2004; 349: 203-11.

- Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome: prevalence and determinants of a "bright" liver echo pattern. *Ital J Gastroenterol Hepatol* 1997;29:351-356.
- London RM, George J. Patogénesis of NASH: Animal Models. *Clin Liver Dis* 2007;11: 55-74.
- Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Croce LS, Grigolato P, Paoletti S, de Bernard B. Proton MR spectroscopy in quantitative in vivo determination of fat content in human steatosis. *J Magn Reson Imaging* 1995;5:281-285.
- López JM, Bennett MK, Sánchez HB, Rosenfeld JM, Osborne TF. Sterol regulation of acetyl coenzyme A carboxylase: A mechanism for coordinate control of cellular lipid. *Proc Natl Acad Sci USA* 1996;93:1049-1053.
- Loria RM, Kibrick S, Madge GE. Infection of hypercholesterolemic mice with Coxackie virus B. *J Infect Dis* 1976;133:655-662.
- Ludwig J, Dickson ER, McDonald GS. Staging of chronic non-suppurative destructive cholangitis (syndrome of primary biliary cirrhosis). *Virchows Arch Pathol Anat* 1978;379:103-12.
- Ludwig J, LaRusso NF, Weisner RH. Primary sclerosing cholangitis. In: Peters RC, Craig JR, eds. *Contemporary issues in surgical pathology, Vol. 8. Liver pathology*. New York:Churchill Livingstone, 1986:193-213.
- Ludwig J, McGill DB, Lindor KD. Review: non-alcoholic steatohepatitis. *J Gastroenterol Hepatol* 1997;12:398-403.
- Ludwig J, Viggiano T, McGill D, Ott B. Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980;55:434-438.
- Luyckx FH, Desai C, Thiry A, Dewé W, Scheen AJ, Gielen JE, Lefèbvre PJ. Liver abnormalities in severely obese subjects: effect of

- drastic weight loss after gastroplasty. *Int Obes Relat Metab Disord.* 1998; 22:222-226.
- MacSween RNM, Burt AD. Histologic spectrum of alcoholic liver disease. *Semin Liv Dis* 1986; 6:221-32.
 - Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RTL. Non-alcoholic steatohepatitis in children and adolescents. *Med J Aust* 2000; 173:476-479.
 - Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology* 2003;37:917-923.
 - Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. *Lancet.* 2001;358:893-894.
 - Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. *Hepatology* 2002;36:1349-1354.
 - Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staeles B. Statin-induced inhibition of the rho-signaling pathway activates PPAR α and induces HDL apoA-I. *J Clin Invest* 2001;107:1423-1432.
 - Masumoto N, Tasaka K, Miyake A, Tanizawa O. Superoxide anion increases intracellular free calcium in human myometrial cell. *J BiolChem* 1990;265:22533-6.
 - Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Kotani K, Tokunaga K. Pathophysiology and pathogenesis of visceral fat obesity. *Obes Res* 1995;3(suppl 2):187S-194S.

- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* 1999; 116:1413-1419.
- McCullough AJ, Falck-Ytter Y. Body composition and hepatic steatosis as precursors for fibrotic liver disease. *Hepatology* 1999;29:1328-1330.
- McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. *Clin Liver Dis* 2004;8:521-533.
- McCullough AJ. Update on nonalcoholic fatty liver disease. *J Clin Gastroenterol* 2002;34:255-262.
- McKenney JM. New cholesterol guidelines, new treatment challenges. *Pharmacotherapy* 2002;22:853-63.
- Miele L, Grieco A, Armuzzi A, Candelli M, Forgione A, Gasbarrini A. Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by ¹³C-octanoate breath test. *Am J Gastroenterol* 2003;98:2335-6.
- Milner JA, Hassan AS. Species specificity of arginine deficiency-induced hepatic steatosis. *J Nutr* 1981;111:1067-1073.
- Mitchell DG. Focal manifestations of diffuse liver disease at MR imaging. *Radiology* 1992;185:1-11.
- Miyagawa J, Kuwajima M, Hanafusa T, Ozaki K, Fujimura H, Ono A, Uenaka R, Narama I, Oue T, Yamamoto K. Mitochondrial abnormalities of muscle tissue in mice with juvenile visceral steatosis associated with systemic carnitine deficiency. *Virchows Arch* 1995;426:271-279.
- Mofrad P, Contos MJ, Haque M, Sageant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ. Clinical and histologic spectrum of non-alcoholic fatty liver disease associated with normal ALT values. *Hepatology* 2003;37:1286-1292.

- Moghadasian MH, Mancini GB, Frohlich JJ. Pharmacotherapy of hypercholesterolaemia: statins in clinical practise. *Expert. Opin. Pharmacother.* 2000;1:683-695.
- Moore C, Shen XD, Gao F, Busuttill R, Coito A. Fibronectin- $\alpha 4\beta 1$ integrin interactions regulate metalloproteinase-9 expression in steatotic liver ischemia and reperfusion injury. *AJP* 2007;170(2):567-577
- Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. *Am J Gastroenterol* 1983;78:374-377.
- Mossab A, Lessire M, Guillaumin S, Kouba M, Mourot J, Peiniau P, Hermier D. Effect of dietary fats on hepatic lipid metabolism in the growing turkey. *Comp Biochem Physiol.* 2002;B132: 473-483.
- Mullen KD, McCullough AJ. Problems with animal models of chronic liver disease: suggestions for improvement in standardization. *Hepatology.* 1989;9:500-3.
- Nagore N, Scheuer PJ. The pathology of diabetic hepatitis. *J Pathol* 1988;156:155-160.
- Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of no-alcoholic steatohepatitis: a pilot open label trial. *Aliment Pharmacol Ther.* 2004;20:23-28.
- Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-sensitivity with simvastatin. *Lancet* 1999;353:1763-4.
- Nakano M, Fukusato T. Histological study on comparison between NASH and ALD. *Hepatology Res* 2005;33:110-115.
- Naoumova RP, Marais AD, Mountney J, Frith JC, Rendel NB, Taylor GW, Thomson GR. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase

- inhibitors in familiar hypercholesterolemia. *Atherosclerosis* 1996; 119: 203-21394.
- Naschitz JE, Yeshurun D, Zuckerman E, Arad E, Boss JH. Massive hepatic steatosis complicating adult celiac disease: report of a case and review of a case and review of the literature. *Am J Gastroenterol* 1987;82:1186-11899.
 - National Cholesterol Education Program Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). *JAMA* 2001;285:2486-2497.
 - National Cholesterol Education Program. Third report of the expert panel on detection, evaluation, and treatment of high cholesterol in adults (Adult Treatment Panel III).
 - Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, Gores GJ. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. *J Hepatol* 2001;34:2448-53.
 - Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight as a risk factor for alcoholic liver disease. *Hepatology* 1997;25:108-111.
 - Nazim M, Stamp G, Hodgson HJ. Nonalcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. *Hepatogastroenterology* 1989;36:349-351.
 - Nemoto Y, Toda K, Ono M, Adachi KF, Saibara T, Onishi S, Enzan H, Okada T, Shizuta Y. Altered constitutive expression of fatty acid-metabolizing enzymes in aromatase-deficient (ArKO) mice. *J Clin Invest* 2000;105:1819-1825.
 - Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment

- with the PPAR-gamma ligand rosiglitazone. *Hepatology* 2003;38:1008-17.
- Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. *Hepatology* 2003;37:1202-1219.
 - Nguyen MTA, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI. JNK and tumor necrosis factor- α mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. *J Biol Chem* 2005;280:35361-71.
 - Noji Y, Higashikata T, Inazu A, Nohara A, Ueda K, Miyamoto S, Kajinami K, Takegoshi T, Koizumi J, Mabuchi H. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. *Atherosclerosis* 2002;163:157-164.
 - Nomura H, Hayashi J, Kajiyama W, Kashiwagi S. Prevalence of fatty liver in a general population of Okinawa, Japan. *Jpn J Med*. 1988;27:521-528.
 - Nonalcoholic steatohepatitis clinical research network. *Hepatology* 2003;35:244.
 - Nonomura A, Enomoto Y, Takeda A. Clinical and pathological features of non-alcoholic steatohepatitis. *Hepatol Res* 2005; 33:116-121.
 - Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S. Tamoxifen-induced fatty liver in breast cancer patients. *Lancet* 1998;351:725.
 - Ogden CL, Troiano RP, Briefel RR, Kuczmarski RJ, Flegal KM, Johnson CL. Prevalence of overweight among preschool children in the United States, 1971 through 1994. *Pediatrics*. 1997;99:E1
 - Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR, MacSween RNM. Cirrhosis with steatohepatitis after adjuvant tamoxifen. *Lancet* 1999;353:36-37.

- Ong JP, Younossi ZM. Nonalcoholic fatty liver disease (NAFLD) two decades later: are we smarter about its natural history? *Am J Gastroenterol* 2003;98:1915-1917.
- Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. *Hepatology* 2002;35 (2):367-372.
- Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. *Gastroenterology*. 1990; 99:1408-1411.
- Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. The effect of reactive oxygen species generated from the mitochondrial electron transport chain on the cytochrome c oxidase activity and on the cardiolipin content in bovine heart submitochondrial particles. *FEBS Lett* 2000;466:323-6.
- Partin JS, Partin JC, Schubert WK, McAdams AJ. Liver ultrastructure in abetalipoproteinemia : evolution of micronodular cirrhosis. *Gastroenterology* 1974 ;67 :107-118.
- Pelleymounter MA, Cullen MF, Baker MB. Effects of the obese gene product on body weight regulation in ob/ob mice. *Science* 1995;269:540-543.
- Perez-Carrera M, Del Hoya P, Ma M, Rubio J, Martín A. Activity of the mitochondrial respiratory chain enzymes is decreased in the liver of patients with non-alcoholic steatohepatitis. *Hepatology* 1999;30:379A.
- Pérez-Carreras M, Del Hoyo P, Martín MA, Rubio JC, Martínez A, Castellano G. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. *Hepatology* 2003;38:999-1007.

- Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. *Semin Liver Dis* 2001;21:57-69.
- Pessayre D, Fromenty B. NASH: a mitochondrial disease. *J Hepatol* 2005;42:928-940.
- Pessayre D, Mansouri A, Fromenty B. Non alcoholic steatohepatitis (NASH): potential cause and pathogenic mechanisms. In: *Hepatology 2000 (Falk Symposium N° 117)* Dordrecht: Kluwer Academic Publisher,2001. p. 57-76.
- Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. *Hepatology* 1994;19:614-627.
- Pinto HC, Baptista A, Camilo ME, Valente A, Saragoça A, de Moura MC. Nonalcoholic steatohepatitis: clinicopathologic comparison with alcoholic hepatitis in ambulatory and hospitalized patients. *Dig Dis Sci* 1996; 41:172-9.
- Poulosom R: Morphological changes of organs after sucrose or fructose feeding. *Prog Biochem Pharmacol* 1986;21:104-134.
- Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. *Hepatology* 1990;11:74-80.
- Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. *Gastroenterology* 1989;97:1022-1024.
- Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for non-alcoholic steatohepatitis. *Hepatology* 2004;39:188-96.
- Purton MD. Structure and ultrastructure of the liver in the domestic fowl (*Gallus gallus*). *Journal of Zoology* 1969;32:73-282

- Quigley EM, Marsh MN, Shaffer JL, Markin RS. Hepatobiliary complications of total parenteral nutrition. *Gastroenterology* 1993;104:286-301.
- Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis : results of a pilot study. *Atherosclerosis* 2004;174(1):193-196
- Ramesh S, Sanyal AJ. Evaluation and management of non-alcoholic steatohepatitis. *J Hepatol.* 2005; 42: 2S-12S.
- Rappaport AM, Borowy ZJ, Lougheed WM, Lotto WN. Subdivision of hexagonal liver lobules into a structural and functional unit; role in hepatic physiology and pathology. *Anat Rec* 1954;119:11.
- Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. *J Pediatr Gastroenterol Nutr* 2000;30:48-53.
- Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. *Hepatology.* 2002 Jun;35(6):1485-93.
- Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. *Gastroenterology* 2005; 128:1898-1906.
- Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault , Theodoriu I. Liver fibrosis in overweight patients. *Gastroenterology* 2000;118:1117-1123.
- Redlich CA, West AB, Fleming L, et al. Clinical and pathologic characteristics associated with occupational exposure to dimethylformamide. *Gastroenterology* 1990;99:748-757.
- Reid AE. Nonalcoholic steatohepatitis. *Gastroenterology* 2001; 121:710-723.

- Reynaert H, Geerts A, Henrion J. Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. *Aliment Pharmacol Ther.* 2005; 22:897-905.
- Roberts EA. Steatohepatitis in children. *Best Pract Res Clin Gastroenterol* 2002;16:749-765.
- Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis: IL Cytochrome P-450 enzymes and oxidative stress. *Am J Physiol Gastrointest Liver Physiol.* 2001;281:G1135-G1139.
- Roglans N, Sanguino E, Peris C, Alegret M, Vázquez M, Adzet T, Díaz C, Hernández G, Laguna JC, Sánchez RM. Atorvastatin treatment induced peroxisome proliferators-activated receptor α expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. *J Pharmacol Exp Ther* 2002;302:232-239.
- Rombouts K, Kisanga E, Hellemans K, Wielant A, Schuppan D, Geerts A. Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. *J Hepatol.* 2003;38(5):564-72.
- Rosman AS, Lieber CS. Diagnostic utility of laboratory tests in alcoholic liver disease. *Clin Chem* 1994;40:1641-1651.
- Ruhl C, Everhart JF. Epidemiology of non-alcoholic fatty liver. *Clin Liver Dis.* 2004; 8: 501-519.
- Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. *Gastroenterology* 2003;124:71-9
- Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsias in the workup of living donors for right lobe liver transplantation. *Liver Transpl* 2002;8:1114-22.
- Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging

- in non-alcoholic fatty liver disease. *Gastroenterology* 2002;123:745-750.
- Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. *Lancet* 1999; 353:1802.
 - Saksena S. Natural history and determinants of disease progression in non-alcoholic fatty liver disease: good and bad news. *Hepatology* 2003;38:232A
 - Sánchez-Alcázar JA, Schneider E, Martínez MA, Carmona P, Hernández-Muñoz I, Siles E. Tumor necrosis factor- α increases the steady state reduction of cytochrome b of the mitochondrial respiratory chain in metabolically inhibited L929 cells. *J Biol Chem* 2000; 275: 13353-61.
 - Sanguino E, Bejarano R, Alegret M, Sánchez RM, Michalik L, Wahli W, Vázquez-Carrera M, Laguna JC. Sexual dimorphism in lipid metabolic phenotype associated with old age in Sprague-Dawley rats. *Exp Gerontol* 2004;39:1295-1306.
 - Sanguino E, Ramón M, Michalik L, Wahli W, Alegret M, Sánchez RM, Vázquez-Carrera M, Laguna JC. Lack of hypotriglyceridemic effect of gemfibrozil and age-related changes in rat liver PPAR α . *Biochem Pharmacol* 2004;67:157-166.
 - Sanguino E, Roglans N, Alegret M, Sánchez RM, Vázquez-Carrera M, Laguna JC. Atorvastatin reverses age-related reduction in rat hepatic PPAR α and HNF-4. *Br J Pharmacol* 2005;145(7):853-861.
 - Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK. Nonalcoholic steatohepatitis association of insulin resistance and mitochondrial abnormalities. *Gastroenterology*. 2001;120:1183-92.
 - Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of tumor necrosis factor- α

- inhibition by pentoxifyline on clinical, biochemical, and metabolic parameters of patients with non-alcoholic steatohepatitis. *Am J Gastroenterol* 2004;99:1946-52.
- Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. *J Hepatol* 1991;13:372-4.
 - Schwimmer JB, Behling C, Newbury R et al. Histopathology of pediatric non-alcoholic fatty liver disease. *Hepatology* 2005;42:641-649.
 - Scott ML, Dean WF. Nutrition and management of ducks. 1991. M. L. Scott of Ithaca, Ithaca, NY.
 - Seilster S, England S: Energy metabolism. En Arias IM (ed): *The Liver: Biology and Pathobiology*, 3rd ed. New York, Raven Press, 1994, p 323.
 - Seitz HK, Xu Y, Simanowski UA, Osswald B. Effect of age and gender on in vivo ethanol elimination, hepatic alcohol dehydrogenase activity, and NAD⁺ availability in F344 rats. *Res Exp Med* 1992;192:205-212.
 - Seki K, Minami Y, Nishikawa M, Kawata S, Miyoshi S, Imai Y, Tarui S. Nonalcoholic steatohepatitis induced by massive doses of synthetic estrogen. *Gastroenterol Jpn* 1983;18:197-203.
 - Seki S, Kitada T, Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. *Hepatol Res* 2005;33:132-4.
 - Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. *J Hepatol* 2002;37:56-62.
 - Senyál AJ. Insulin resistance and nonalcoholic fatty liver disease. In: Arroyo V, Navasa M, Foras X, Bataller R, Sanchez-Fueyo A, Rodés J. editors. *Update in treatment of liver disease*. Barcelona: Ars Medica; 2005. p. 279-296.

- Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. *World J Gastroenterol* 2003;9:1106-10.
- Sheuer P. Primary biliary cirrhosis. *Proc R Soc Med* 1967;60:1257-60.
- Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. *J Clin Invest* 1996;98:1575-1584.
- Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. *Nature*. 1999;401:73-6.
- Siddiqui J, Raina D, Abraham A, Alla V, Chalasani N, Wu GY, Bonkovsky HL. Autoimmune hepatitis induced by statins [abstract]. *Gastroenterology* 2005;128:A171.
- Siegmund B, Lehr HA, Fantuzzi G. Leptin: a pivotal mediator of intestinal inflammation in mice. *Gastroenterology*. 2002;122:2011-25.
- Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. *Pathol Annu* 1989;24 Pt 1:275-302.
- Simonson SG, Martin PD, Mitchell P, Schneck DW, Lasseter KC, Warwick MJ. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. *Eur J Clin Pharmacol* 2003;58:669-675.
- SKelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. *J Hepatol* 2001;35:195-199.
- Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: The yield of transaminase and creatine kinase

- measurements in a primary care setting. *Arch Intern Med* 2003;163:688-692.
- Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring for statin use?. *Am J Cardiol* 2004; 94(suppl):30F-34F.
 - Solís-Herruzo JA, De La Torre P, Muñoz-Yagüe MT. Hepatic stellate cells: Architects of hepatic fibrosis. *Rev Esp Enferm Dig* 2003;95:438-9.
 - Solis-Herruzo JA, Vidal JV, Colina F, Castellano G, Muñoz-Yagüe MT, Morillas JD. Clinico-biochemical evolution and late hepatic lesions in the toxic oil syndrome. *Gastroenteology* 1987;93:558-568.
 - Sorrentino P, Tarantino G, Conca P, Perrella A, Terracciano ML, Vecchione R, Gargiulo G, Gennarelli N, Lobello R. Silent non-alcoholic fatty liver disease a clinical histological study. *J Hepatol* 2004;41: 751-757.
 - Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. *N Engl J Med* 2002;346:539-40.
 - Stamler J, Wentworth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension: prospective data on the primary screenees of the multiple risk factor intervention trial. *Am J Med* 1986;80:33-9.
 - Steiner J, Miyai JW, Phillips M. Electrón microscopy of membrana-particle arrays in liver cells of ethionine-intoxicated rats. *Amer J Path* 1964; 44:169-214.
 - Stevens L. *Avian biochemistry and molecular biology*. 1996. Cambridge University Press, Cambridge, UK
 - Stibler H. Carbohydrate deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. *Clin Chem* 1998; 37:2029-2037.

- Stromeyer FW, Ishak KG. Histology of the liver en Wilson's disease: a study of 34 cases. *Am J Clin Pathol* 1980;73:12-24.
- Takahashi T, Kamaimura T, Ichida H. Ultrastructural findings on polymorphonuclear leucocyte infiltration and acute hepatocellular damage in alcoholic hepatitis. *Liver* 1987; 7: 347-58.
- Tanaka H, Furusto M, Takasaki S. Morphological and biochemical alteration in the rat liver induced by maprotiline. *Acta Path Jap* 1975; 25: 413-437.
- Tanzawa, K, M. Kuroda, and A. Endo. Time dependent, irreversible inhibition of 3-hydroxy-3-methyl-glutaril coenzyme A reductase by the antibiotic citrinin. *Biochim. Biophys. Acta.* 1977;488: 97-101.
- Tarugi P, Lonardo A, Ballarini G, et al. Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. *Gastroenterology* 1996;111:1125-1133.
- Teli MR, Day CP, Burt AD, et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. *Lancet* 1995;346:987-990.
- Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of non-alcoholic fatty liver: a follow-up study. *Hepatology* 1995;22; 1714-1719.
- Toda T, Nishimori I, Kummcrow F. Animal model of atherosclerosis: experimental atherosclerosis in the chicken animal model. *Jpn Atheroscler Soc* 1983;11:755-760.
- Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. *Dig Dis Sci* 1995;40:2002-9.

- Tontonoz P, Hu E, and Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. *Cell*. 1994;79:1147-1156
- Torezan-Filho MA, Alves VA, Neto CA, Fernandes HS, Strauss E. Clinical significance of elevated alanine aminotransferase in blood donors: a follow-up study. *Liver Int* 2004;24:575-681.
- Tsukamoto H, Horne W, Kamimura S, Niemelä O, Parkkila S, Ylä-Herttuala S, Brittenham GM. Experimental liver cirrhosis induced by alcohol and iron. *J Clin Invest* 1995;96:620-630.
- Tuomainen TP, Nyysönen K, Salonen R, Tervahauta A, Korpela H, Lakka T, et al. Body iron stores are associated with serum insulin and blood glucose concentrations. *Diabetes Care*.1997;20:426-8.
- Ueno T, Singawara H, Sujaku K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. *J Hepatol*. 1997; 27: 103-107.
- Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2004;19:537-44.
- Vanderhoof JA, Metz MJ, Tuma DJ, et al. Effect of improved absorption on development of jejunoileal bypass induced liver dysfunction in rats. *Dig Dis Sci* 1980;25:581-586.
- Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. *Lancet* 1996;348:1079-1082.
- Wagner BA, Buettner GR, and Burns CP. Free radical-mediated lipid peroxidation in cells: oxidizability is a function of cell lipid bis-allylic hydrogen content. *Biochemistry*. 1994;33:4449-4453.
- Wallace DC. Mitochondrial disease in man and mouse. *Science* 1999;283:1482-8.

- Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. *Endocrinology* 2006;147:943-51.
- Wanles IR, Bargman JM, Orepoulos DG, Vas SI. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the patogénesis of steatonecrosis in obesity. *Mod Pathol* 1989;2:69-74.
- Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. *Hepatology* 1990;12:1106-10.
- Wasserman J, Thung SN, Berman R, Bodenheimer H, Sigal SH. Hepatic Weber-Christian Disease. *Semin Liver Dis* 2001;21(1):115-118.
- Weiss L: *Histology*, 5^a. ed. Nueva Cork, Elsevier, 1983, p 713.
- Weltman M, Farrell G, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with non-alcoholic steatohepatitis. *Hepatology*. 1998;27:128-133.
- Whelan G, Wood B. The metabolic consequences of jejunioileal bypass for obesity. *Aust N Z J Surg* 1980;50:520-524.
- Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. *Gut* 2001;48:206-211.
- Willis RA, Folkers K, Tucker JL, Ye C-Q, Xia L-J, Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. *Proc Natl Acad Sci USA* 1990; 87: 8928-8930
- World Health Organization. Nutrition. Controlling the global obesity epidemic. Available at: www.who.int/nut/obs.htm (accessed Nov 2004).
- Yamamoto A, Hoshi K, Ichihara K. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and

- inhibits lipid peroxidation in rat liver microsomes. *Eur J Pharmacol* 1998;361:143-9.
- Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipodystrophy and obesity. *Nat Med* 2001;7:941-6.
 - Yang S, Koteish A, Lin H, Huang J, Roskams T, Dawson V, Diehl AM. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. *Hepatology* 2004; 39:403-411.
 - Yatsuji S, Hashimoto E, Kaneda H. Characteristic features and risk factors for hepatocellular carcinoma in non-alcoholic steatohepatitis. *Hepatology*. 2005;42:625A.
 - Yki-Järvinen H. Thiazolidinediones. *N Engl J Med*. 2004; 351:1106-1118.
 - Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with non-alcoholic steatohepatitis. *Hepatology* 2004;40:1222-5.
 - Yoshikawa T, Toda K, Nemoto Y, Ono M, Iwasaki S, Maeda T, Saibara T, Hayashi Y, Miyazaki E, Hiroi M et al. Aromatase-deficient (ArKO) mice are retrieved from severe hepatic steatosis by peroxisome proliferator administration. *Hepatology Res* 2002;22:278-287.
 - Yost RL, Duerson MC, Russell WL, et al. Doxycycline in the prevention of hepatic dysfunction: an evaluation of its use following jejunoileal bypass in humans. *Arch Surg* 1979;114:931-934.
 - Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. *Hepatology* 2002;35:746-752.

- Younossi ZM, Gramlich T, Liu YC, Matteoni C. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. *Mod Pathol* 1998;11:560-565
- Youssef WI, McCullough AJ. Diabetes mellitus, obesity, and hepatic steatosis. *Semin Gastrointest Dis* 2002;13:17-30.
- Yu AS, Keefe EB. Elevated AST o ALT to non-alcoholic fatty liver disease: accurate predictor of disease prevalence? (editorial). *Am J Gastroenterol* 2003;98:955-956.
- Zalber-Sagi S, Lurie Y, Nitzan-Kaluski, Halpern Z, Oren R. Serum ALT is not a reliable screening tool for NAFLD in the general population. *J Hepatol* 2006;44 (Supl 2): S267.
- Zeviani M, Tiranti V, Piantadosi C. Mitochondrial disorders. *Medicine* 1998;77:59-72.
- Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts; 1978:181-185, 363-364.
- Ziol M, Tepper M, Lohez M, et al. Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis. *J Hepatol* 2001; 34:254-60.